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ABSTRACT 
Charles University in Prague, Faculty of Pharmacy in Hradec Králové  
Department of Pharmaceutical Chemistry and Pharmaceutical Analysis 
Student: Anastasia Katirtzi 
Supervisor: Assoc. Prof. RNDr. Veronika Opletalová, Ph.D. 
Title of Diploma Thesis: Amidoximes as intermediates for the synthesis of potential drugs 
 
The current thesis is focused on the O-acylation of pyrazine amidoximes and their 
cyclization to the corresponding 3,5-disubstituted- 1,2,4-oxadiazoles. 5-unsubstituted and 
5-butylpyrazine amidoximes were acylated by acetic anhydride, trimethylacetic anhydride and 
2,3-pyrazinecarboxylic anhydride as acylating agents in toluene. Formation of oxadiazoles was 
achieved in xylene, using acetic anhydride for acylation. Identification of the products was 
done by melting points, NMR and IR spectra, and their purity was proved by elemental analysis 
Furthermore, amidoximes and their derivatives were subjected to biological assay in order to 
evaluate their in vitro antifungal and antibacterial properties. Unfortunatelly, amidoximes and 
1,2,4-oxadiazoles were inactive. For the esters, biological results will be available later.
ABSTRAKT 
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Tato práce je zaměřena na O-acylaci amidoximů odvozených od pyrazinu a jejich 
cyklizaci na odpovídající 3,5-disubstituované-1,2,4-oxadiazoly. 5-nesubstituovaný 
a 5-butylpyrazinamidoxim byly acylovány anhydridem kyseliny octové, resp. anhydridem 
kyseliny trimethyloctové, v toluenu. Oxadiazoly byly připraveny zahříváním amidoximů 
s anhydridem kyseliny octové v xylenu. Identificace produktů byla provedena na základě 
teploty tání, NMR a IČ spekter a čistota ověřena elementární analýzou. U amidoximů a jejich 
derivátů byly dále testovány in vitro jejich antifungální a antibakteriální vlastnosti. Amidoximy 
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Amidoximes are very versatile compounds, and their chemical properties and biological 
effects have previously been reviewed [1–12]. In drug discovery and design, they have been 
studied as prodrugs of amidines. Ximelagatran is a prodrug which is converted to direct 
thrombin inhibitor melagatran by hydrolysis of the ester group and reduction of the amidoxime 
moiety. It seemed to be very promising drug since the introduction of warfarin, there have been 
no new anticoagulants for about 50 years Ximelagatran was used for a limited time as the 
preparation EXANTA. In 2006, it was withdrawn because of serious hepatotoxicity. 
Nonetheless, it is still used as an important pharmacological tool to study pathogenesis of 




Many studies have been devoted to amidoxime-prodrugs of antiprotozoal drug 
pentamidine and its analogues [18–26]. Esters of pentamidine-amidoximes with dicarboxylic 
acids have been patented as potential therapeutic or prophylactic agents against cancer, 





Hydroxylated amidines, guanidines and amidrazones have been patented as components 
for transdermal therapeutic systems [29, 30]. Orally available amidoxime prodrug has recently 




Amidoxime have also been studied as potential NO (nitric oxide) donors since they liberate 
NO by nitric oxide synthase (NOS) independent mechanisms [32–36]. 
Amidoxime derivative BGP-15 is an inhibitor of poly(ADP-ribose)polymerase and a heat 
shock proteins (HSP) inducer. It acts as a protective agent against side effects of other drugs 
[37–39] and has a positive effect on various conditions, such as neuronal injury and aging [40, 
41], muscular dystrophy [42, 43], arthritis [44] and insulin resistance [45–49]. Currently, in 
undergoes clinical studies as a potential antidiabetic drug [49, 50]. BGP-15 and its analogues 
have also been patented as compounds that ameliorate the tissue regeneration effect of adult 










2. Aim of the work 
Research concerning amidoximes commenced at the Department of Pharmaceutical 
Chemistry and Pharmaceutical Analysis in 2011. At that time, Horká prepared a series of 




General formula of pyrazine-amidoximes prepared by Horká 
R = propyl, isopropyl, pentyl, hexyl 
 
The compounds were tested for the antibacterial and antifungal activities. Although 
antibacterial effects of amidoximes have previously been reported [52–56], some heterocyclic 
amidoximes have been patented as agricultural fungicides [57, 58] and some amidoximes 
exhibited activity against Aspergillus spp. [56] the pyrazine-amidoximes were inactive in the 
assays performed at the Department of Biological and Medical Sciences. Therefore it was 
decided to prepare and test additional amidoximes and their derivatives. 
Modifications of amidoxime group can yield N-substituted derivatives, O-substituted 
derivatives, N,O-disubstituted derivatives and cyclic analogues. My diploma work will be 





3. Theoretical part  
3.1 Acylation of amidoximes 
Generally, acylation of amidoximes is done easily by anhydrides or acid chlorides [1]. It 
can also been performed using carboxylic acids activated by DCC, EDC, CDI, TBTU, HOBt 
or HBTU [59].  Special methods of acylation have also been described [2, 8, 11, 60]. 
 
 
Scheme 1 Acylation of amidoximes 
 
Amidoximes exist in two tautomers I and II, and it has been confirmed by IR and NMR 
spectra and other studies that the former tautomer is more stable [61–64]. They represent 
a special group of α-nuclephiles within the series of efficient acyl group acceptors – 
hydroxamic acids, oximes, and amidoximes. Although they are structurally similar to oximes, 
their kinetic behavior in reactions with the halides and esters of phosphorus and carboxylic 
acids differes substantially from kinetic behavior of oximes. In the case of oximes, the acceptor 
of the acyl group is the oximate anion. In amidoximes, both neutral and the anionic forms act 
as nucleophilic reagents [65]. 
 
 
Scheme 2 Acylation of amidoximes (adopted and modified from the ref. [65]) 
 
Irrespective of which form (neutral or anionic) reacts with the acylating reagent, the 
reaction product is always O-acylderivative [64, 65], except for formamidoxime where both 





Nucleophilicity of of nitrogen in NH2 group is lower than that in normal NH2 moiety due 
to mesomerism and formation of iminium cation C-NH2 to C=NH2+. Thus electron density and 
nucleophilicity of OH- moiety is improved and acylation at this moiety takes place [67, 68].  
 
 
Scheme 3 Resonance forms of amidoximes (adopted and modified from ref. [69]) 
 
Acyl derivatives of amidoximes have basic character, no acidic like starting ones. This 
proves that isonitroso group is involved in acylation reaction. Additionally, the absence of OH 
absorption and the presence of NH2 and –O-CO groups is obvious from IR spectra [1, 70]. 
 
3.1.1 Acylation of amidoximes with anhydrides 
Acylation of amidoximes with anhydrides can be limited by the lack of commercially 
available anhydrides [67]. Eloy and co-workers [66] performed acetylation of formamidoxime 
using acetic anhydride or mixed acetic (ethyl carbonic) anhydride. In both cases, they obtained 




The advantage of the reaction with acetic (ethyl carbonic) anhydride is that no acetic acid, 





Acetylation of the amidoxime derived from a sugar was performed by acetic anhydride in 




Acetanhydride was also used to prepare O-acetylderivatives of acetylhydracrylamidoxime 
and ethoxycarbonylhydracrylamidoxime. It these cases acetic anhydride (without a solvent) 






Formylation of acetamidoxime was performed by means of mixed acetic formic anhydride 






Nʹ-Acetoxypyrazine-2-carboximidamide was obtained by heating Nʹ-hydroxypyrazine-




Heating of DL-2-amino-Nʹ-hydroxy-3-phenylpropanimidamide with acetic anhydride and 




Benzamidoximes, where R = H, 4-N(CH3)2, 4-OCH3, 4-Br, 3-Cl, 4-NO2, gave acetylated 





The same reaction conditions were use to prepare N-3 funtionalized 
3,4-dihydropyrimidine-2(1H)-ones, where ionic liquid bound amidoxime reacted with acetic 






Anhydrides were applied also by other researchers [75–78]. 
 
3.1.2 Acylation of amidoximes with acyl chlorides 
Acyl chlorides are very effective acylating agents and have been used for the preparation 
of both acylated [66, 67, 79, 80] and aroylated [61, 66, 67, 70, 72, 73, 75, 77, 81–84] 
amidoximes.  
Bell and co-workers [61] prepared O-benzoylacetamidoxime using benzoyl chloride in 




Benzoylchloride in pyridine was also used by Tsiulin et al. [82]. They performed the 
reaction at 80 °C. Equimolar amounts of the reactants were used. According to the IR data, the 
product was formed immediately after mixing solutions of N-hydroxybenzimidamide and 
benzoyl chloride in pyridine at 100°C, and the initial reactants are consumed completely. The 







When DL-2-amino-Nʹ-hydroxy-3-phenylpropanimidamide in ethyl acetate was mixed 
with benzoyl chloride and aqueous potassium carbonate dibenzoylated derivative was formed 




Ooi and Wilson [73] prepared a series of aroylated acetamidoximes by stirring 
acetamidoxime with aqueous sodium hydroxide. The solution was then filtered and treated 
with with the aroyl chloride, and the aroylated product was obtained. Similar procedure was 




Reaction of N-{4-[2-amino-2-(hydroxyimino)ethyl]phenyl}acetamide with acyl- or aroyl 
chlorides after addition of anhydrous K2CO3 in 1,4-dioxane under room temperature leads to 





Chloroacetyl chloride acylates amidoximes in acetone at ambient temperature after 




One efficient method generating O-p-bromobenzoyl-β-(4-phenylpiperazine-1-yl) 
propioamidoximes is by adding p-bromobenzoyl chloride in CHCl3 to a mixture of amidoxime 




O-perfluoroacyl perfluoroacyl amidoximes were derived by treatment of perfluoroacyl 
amidoxime in anhydrous ether solution with perfluoroacyl chloride at room temperature for 





Acyl and aroyl chlorides were used as well by other researchers [66, 67, 70, 75, 77, 81]. 
 
 
3.2 Synthesis of 1,2,4-oxadiazoles 
Oxadiazoles are on the focus of the research [1, 9, 67, 75, 76, 78–83, 85–89] because they 
are isosteres of esters and amides and this is the explanation supporting that they have similar 
biological properties with them. They can grant a big series of H3-antagonists, monoamine 
oxidase inhibitors (MAOI), drugs against tumors or against inflammation, muscarinic 
antagonists, tyrosine kinase inhibitors [86]. Others showed antiparasitic, coronary artery 
dilating, myorelaxant, aldose reductase inhibiting and anesthetic activities [87]. Some 
oxadiazoles were tested as inhibitors of glycogen phosphorylase (GP) [88].  




Scheme 4 Preparation of 1,2,4-oxadiazoles 
 
It is clear that oxadiazoles are formed in two step reaction, acylation and cyclization [67, 
79–83]. The synthesis can be performed as a one-pot reaction without isolating the intermediate 
ester or in two steps. Thus, 5-substituted 3-C-β-D-glucopyranosyl-1,2,4-oxadiazoles (where R 
= benzyl) were prepared by heating the corresponding acylated amidoximes using a one-pot 
procedure, while  in the case of 3-C-β-D-glucopyranosyl-1,2,4-oxadiazoles (where R = 






3.2.1 Procedures with the isolation of acylated intermediate 
N-{4-[(5-substituted-1,2,4-oxadiazol-3-yl)methyl]phenyl}acetamides were generated in 
two step pathway too. Firstly, acylated amidoximes were prepared according to reaction (14). 
Second step was submission of the intermediate to reflux in toluene and N,N-




3,5-bis(perfluoroalkyl)-1,2,4-oxadiazoles synthesis includes the treatment of 
O-perfluoroacyl perfluoroacyl amidoxime with phosphorus pentoxide at 250–300℃ for 12–24 






Various alkanoyl or aroyl amidoximes, prepared with a suitable acylator (acid anhydride 
or chloride) in dichloromethane in the presence of diisopropylethylamine, were further 
cyclized with tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF) at 23 °C. It was 
found that a catalytic amount of TBAF could facilitate conversion of starting amidoximes and 
that reaction times were significantly shorter when 1.0 equivalent of TBAF was used. The 
reaction times were also dependent on the solvent used. Acetonitrile was comparable with 
THF, dichloromethane was less suitable. No oxadiazole formation was observed in the absence 
of TBAF, only trifluoromethyl benzamidoxime (R = phenyl, R1 = CF3) cyclized spontaneously 




Benzoylated benzamidoximes synthesized according to reaction (11) were further cyclized 






The cyclization was performed in the following solvents: glacial acetic acid, pyridine, 
1,4-dioxane and toluene. Equimolar amounts of the reagents were used and the reaction 
mixture was heated to 100 °C. To study reaction kinetic, benzoyl chloride was quickly added 
to the benzoylated amidoxime and samples of the reaction mixture were taken during the 
process and diluted with 15–20 volumes of acetonitrile. The reaction rate was determined from 
the accumulation of final product which was quantitated by HPLC [82]. 
It was found that the cyclization can be described by first-order kinetic equation. It is 




Fig. 1 Cyclization of Nʹ-(benzoyloxy)benzimidamide in (1) glacial acetic acid, (2) pyridine, 
(3) 1,4-dioxane, and (4) toluene; cIII is the concentration of the oxadiazole (adopted from ref. 82) 
 
Chloroacetyl chloride reacts with amidoxime in acetone at room temperature for 
30 minutes as shown in reaction (15). O-chloroacetyl derivative produced is put under reflux 




In a similar way benzamidoxime acylated with 2-chloropropanoyl chloride in 






Cyclization can also be performed in a solvent-free manner. For instance, O-acetyl-4-
bromobenzamidoxime prepared by acetylation of the corresponding amidoxime leads to 3-(4-




3.2.2 One-pot procedures without the isolation of acylated intermediate 
The latter compound was also prepared using one-pot procedure in which 
4-bromobenzamidoxime was heated with acetic anhydride for 3–4 minutes. One-pot procedure 




One-pot procedures were also used by other researchers [79, 80, 86–89].  
24 
 
To prepare N-[4-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)methyl)phenyl]acetamide the 
authors [79] used one-pot reaction of starting amidoxime with trifluoroacetic anhydride 
(TFAA) in a mixture of anhydrous dichloromethane (CH2Cl2) and triethylamine (Et3N) at 45  C 




For the synthesis of 3,5-bis(perfluoroalkyl)-1,2,4-oxadiazoles two modifications of the 
method depicted in reaction (20) were found in which acylation and dehydratation were 
achieved in one step. In the first one, perfluorobytyryl chloride functioned as both acylating 




In the second modification, perfluorobutyramidoxime was mixed with phosphorus 
pentoxide and perfluorobutyric acid. The reaction mixture was then refluxed for 6 hours. The 
reaction probably involves initial formation of perfluorobutyric anhydride, which acylates the 







Rice and Nuss [86] performed synthesis of 3,5-disubstituted-1,2,4-oxadiazoles on the solid 
support using tetra-N-butylammonium fluoride (TBAF) for the cyclodehydration of 
O-acylamidoximes. Nitriles bound to Agropore MB-CHO resin were converted to amidoximes 
using a range of acid chlorides. Subsequent treatment with TBAF in THF under ambient 
conditions gave a library of 3,5-disubstituted-1,2,4-oxadiazoles. All reactions steps were 






A profitable and more enviromentally friendly method for the preparation of 
3,5-disubstituted-1,2,4-oxadiazoles could be working without a solvent, aided by microwave 
irradiation, catalyzed and solid supported by potassium fluoride. It is a one-pot synthesis 




In order to assess the ability of potassium fluoride to catalyze the reaction, sodium 
carbonate and sodium bicarbonate were examined also, using p-chlorobenzoyl chloride as 




Polyák and co-workes [88] prepared 5-aryl-N-(2,3,4,6-O-acetyl-β-D-glucopyranosyl)-





3,5-disubstituted-1,2,4-oxadiazoles were also obtained by reacting benzamidoximes with 
benzoyl cyanides in various solvents (1,4-dioxane, toluene, DMF, acetonitrile) at different 
temperatures under both conventional as well as microwave heating conditions. It was found 
that microwave irradiation decreased the reaction time and increased the yields of the target 
compounds. DMF proved to be the most convenient solvent [89]. The authors also stated that 
the cyclization was promoted by electron-donating substituents on the amidoxime benzene 
ring, which in agreement with the conclusions of Tsiulin and co-workers [82]. On contrary, 




One-pot procedure was also used by Fanshawe and Safir [90–92] who prepared 
3,5-disubstituted-1,2,4-oxadiazoles by heating amidoximes with an acid anhydrides or 








4. Experimental part 
Commercially available substances were used for the preparation for the substances prepared 
in this thesis: 
 pyrazinecarbonitrile, 99% (Aldrich) 
 hydroxylamine hydrochloride, p.a. (Lachema)  
 acetic anhydride, pure (Penta)  
 trimethylacetic anhydride, 99% (Aldrich) 
 2,3-pyrazinedicarboxylic anhydride, 97% (Aldrich) 
 
TLC was performed on TLC aluminium sheets, silica gel 60 F254 (Merck). Light petroleum + 
ethyl acetate 60:40 (v/v) and toluene: acetone 70:30 were used as a mobile phases. 
 
For analysis, the samples of compounds were dried 24 hours in the dessicator over anhydrous 
phosphorus pentoxide at 1.33 kPa and room temperature. 
 
Melting points were determined using Melting Point Apparatus SPM 20 (Stuart) and are 
uncorrected. 
 
Elemental analyses were performed with the EA 1110 CHNS Analyzer (Carlo Erba). 
 
IR spectra were recorded with the spectrophotometer NICOLET 6700 using ATR-Ge method. 
Wavenumbers are given in cm-1. 
 
1H NMR a 13C NMR spectra were recorded with the VARIAN Mercury-VxBB 300 
spectrometer operating at 300 MHz for 1H and 75 MHz for 13C or VNMR S500 spectrometer 
operating at 500 MHz for 1H NMR and 125 MHz for 13C NMR). Chemical shifts were recorded 
as δ values in ppm and were indirectly referenced to tetramethylsilane (TMS) via the solvent 







To a solution of pyrazinecarbonitrile (10.5 g, 0.1 mol) in water (300 ml) heated to 80 °C, 
silver nitrate (1.7 g, 0.01 mol) and the valeric acid (10.2 g, 0.1 mol) were added. Ammonium 
peroxydisulfate (25.1 g, 0.11 mol) in water (70 ml) was then added dropwise whilst stirring 
and temperature maintained between 75–80 °C. The reaction mixture was stirred for 1 h. After 
cooling, the pH was adjusted to 9 with 10% solution of sodium hydroxide, and the mixture was 
continuously extracted with diethyl ether. The organic extract was dried over anhydrous 
sodium sulfate and filtrated. 
The filtrate was adsorbed to 150 g Silica gel 60 Fluka, 0.063–0.200 mm and subjected to 
column chromatography using light petroleum + ethyl acetate 80:20 the mobile phase. 
Repeated chromatography yielded 6.2 g (40%) of a yellowish liquid, TLC of which 




4.2 Nʹ -hydroxypyrazine-2-carboximidamide 
 
 
Pyrazine-2-carbonitrile (6.3 g; 0.06 mol) was diluted with 9 ml of ethanol. Hydroxylamine 
hydrochloride (8.34 g; 0.12 mol) was dissolved in 9 ml of water, and the solution was added 
to the ethanolic solution of the nitrile. Sodium carbonate (12.72 g; 0.12 mol) was dissolved in 
75 ml of water and added cautiously to the reaction mixture. The mixture was then heated 
under reflux condenser at 70 C for 5 hours and left standing at room temperature overnight. 
The crystals were separated through a sintered glass and washed with water. 7.82 g (94%) of 
the crude product was obtained. Crystallization from anhydrous ethanol gave 6.64 g (80%) of 
white needles. 
 
Molecular weight: 138.13 (C5H6N4O) 
Melting point: 185–187 °C (ref. [53]: 186–187 °C, methanol; ref. [94]: 185–186 °C, 
sublimation) 
Elemental analysis: 
 % C % H % N 
Calculated: 43.48 4.38 40.56 
Found: 43.62 4.64 40.36 
 
IR spectrum: 3434, 3300 (assoc. NH), 3147 (assoc. OH), CH, (pyrazine), 1659 (C=N), 953 
(N-O) 
1H NMR spectrum (300 MHz, DMSO) δ 10.23 (1H, s, OH), 9.05 (1H, d, J = 1.4, H3), 8.64–
8.59 (2H, m, H5, H6), 5.95 (2H, bs, NH2)  






5-Butylpyrazine-2-carbonitrile (6.20 g; 0.038 mol) was diluted with 5.7 ml of ethanol. 
Hydroxylamine hydrochloride (5.28 g; 0.076 mol) was dissolved in 5.7 ml of water, and the 
solution was added to the ethanolic solution of pyrazine-2-carbonitrile. Sodium carbonate (8.06 
g; 0.081 mol) was dissolved in 47.5 ml of water and added cautiously to the reaction mixture. 
The mixture was then heated under reflux condenser at 70 C for 5 hours. After cooling, the 
crystals were separated through a sintered glass and washed with water. 5.9 g (79%) of the 
crude product was obtained. Crystallization from anhydrous ethanol gave 3.89 (52%) of 
colorless needles. 
Molecular weight: 194.24 (C9H14N4O) 
Melting point: 154–155 °C 
Elemental analysis: 
 % C % H % N 
Calculated: 55.65 7.27 28.85 
Found: 55.44 7.01 28.20 
 
IR spectrum: 3431, (assoc. NH), 3179 (assoc. OH), 2955, 2928, 2862 (CH, aliph.), 1661 (C=N), 
945 (N-O) 
1H NMR spectrum (500 MHz, DMSO) δ 10.11 (1H, s, OH), 8.96 (1H, s, H3), 8.50 (1H, s, H6), 
5.90 (2H, bs, NH2), 2.78 (2H, t, J = 7.6, CH2), 1.71–1.61 (2H, m, CH2), 1.36–1.26 (2H, m, 
CH2), 0.89 (3H, t, J = 7.6, CH3) 









Nʹ-Hydroxypyrazine-2-carboximidamide (0.69 g; 0.005 mol) was suspended in toluene 
(100 ml). Acetic anhydride (0.51 g; 0.005 mol) was added, and the mixture was refluxed for 
1 hour. Toluene was removed in vacuum and 0.73 g (81%) of the crude product was obtained. 
Crystallization from anhydrous ethanol gave 0.66 g (73%) of colorless needles. 
 
Molecular weight: 180.17 (C7H8N4O2) 
Melting point: 152–153 °C (ref. [71]: 168–169 °C, benzene)  
Elemental analysis: 
 % C % H % N 
Calculated: 46.67 4.48 31.10 
Found: 46.85 4.71 31.23 
 
IR spectrum: 3436, 3352 (assoc. NH), 1744 (C=O), 1624 (C=N) 
1H NMR spectrum (300 MHz, DMSO) δ 9.10 (1H, d, J = 1.4, H3), 8.78 (1H, d, J = 2.5, H6), 
8.73 (1H, dd, J = 2.5, J = 1.4, H5), 7.08 (2H, bs, NH2), 2.17 (3H, s, CH3) 






5-Butyl-Nʹ-hydroxypyrazine-2-carboximidamide (0.97 g; 0.005 mol) was suspended in 
toluene (100 ml). Acetic anhydride (0.51 g; 0.005 mol) was added, and the mixture was 
refluxed for 1 hour. Toluene was removed in vacuum and 1.10 g (93%) of the crude product 
was obtained. Crystallization from anhydrous ethanol gave 0.91 g (77%) of colorless flakes. 
 
Molecular weight: 236.27 (C10H13N4O2) 
Melting point: 130–132 °C 
Elemental analysis: 
 % C % H % N 
Calculated: 55.92 6.83 23.71 
Found: 55.72 6.27 23.39 
 
IR spectrum: 3428, 3315 (assoc. NH), 2962, 2930, 2859 (CH, aliph.), 1762 (C=O), 1632 (C=N) 
1H NMR spectrum (300 MHz, DMSO) δ 8.97 (1H, d, J = 1.5, H3), 8.60 (1H, d, J = 1.5, H6), 
7.00 (2H, bs, NH2), 2.82 (2H, t, J = 7.6, CH2), 2.15 (3H, s, CH3), 1.73–1.58 (2H, m, CH2), 
1.38–1.21 (2H, m, CH2), 0.88 (3H, t, J = 7.6 , CH3) 







Nʹ-Hydroxypyrazine-2-carboximidamide (0.69 g; 0.005 mol) was suspended in toluene 
(100 ml). Pivalic anhydride (0.93 g; 0.005 mol) was added, and the mixture was refluxed for 1 
hour. Toluene was removed in vacuum and 1.10 g (97%) of the crude product was obtained. 
Crystallization from anhydrous ethanol gave 0.75 g (66%) of colorless needles. 
Molecular weight: 222.25 (C10H14N4O2) 
Melting point: 156–157 °C 
Elemental analysis: 
 % C % H % N 
Calculated: 54.04 6.35 25.21 
Found: 54.53 6.60 25.75 
 
IR spectrum: 3498, 3382 (assoc. NH), 2981, 2937 (CH, aliph.), 1743, 1736 (C=O), 1625 (C=N) 
1H NMR spectrum (300 MHz, DMSO) δ 9.09 (1H, d, J = 1.2, H3), 8.78 (1H, d, J = 2.4, H6), 
8.74–8.71 (1H, m, H5), 6.89 (2H, bs, NH2), 1.25 (9H, s, CH3)          








5-Butyl-Nʹ-hydroxypyrazine-2-carboximidamide (0.97 g; 0.005 mol) was suspended in 
toluene (100 ml). Pivalic anhydride (0.93 g; 0.005 mol) was added, and the mixture was 
refluxed for 1 hour. Toluene was removed in vacuum and 0.87 g (63%) of the crude product 
was obtained. Crystallization from anhydrous ethanol gave 0.73 g (53%) of colorless needles. 
 
Molecular weight: 278.36 (C14H22N4O2) 
Melting point: 158–159 °C 
Elemental analysis: 
 % C % H % N 
Calculated: 60.41 7.97 20.13 
Found: 60.89 8.25 20.68 
 
IR spectrum: 3400, 3296 (assoc. NH), 2963, 2930, 2872 (CH, aliph.), 1746 (C=O), 1639 (C=N) 
1H NMR spectrum (300 MHz, DMSO) δ 8.97 (1H, d, J = 1.5, H3), 8.62 (1H, d, J = 1.5, H6), 
6.82 (2H, bs, NH2), 2.83 (2H, t, J = 7.5, CH2), 1.75–1.58 (2H, m, CH2), 1.39–1.22 (2H, m, 
CH2), 1.25 (9H, s, CH3), 0.89 (3H, t, J = 7.5, CH3)        
13C NMR spectrum (75 MHz, DMSO) δ 174.9, 159.1, 153.2, 143.0, 142.0, 141.7, 38.5, 34.3, 









Nʹ-Hydroxypyrazine-2-carboximidamide (0.69 g; 0.005 mol) was suspended in toluene 
(100 ml) and heated until the amidoxime dissolved. Anhydride of 2,3-pyrazinedicarboxylic 
acid (0.75 g; 0.005 mol) was then added. A solid started to precipitate immediately. The 
mixture was refluxed for 1 hour (the precipitate did not dissolve during heating). After cooling, 
the solid was filtered off, washed with a small of toluene and a small amount of ethanol. After 
drying, 1.05 g of an off-white powder was obtained. According to TLC results, this substance 
was a mixture of two compounds, therefore it was subjected to column chromatography on 
silica gel 60, 0.040 – 0.063 (Merck) using a mixture of light petroleum and ethyl acetate 40:60 
as the mobile phase. Volume of one fraction was 20 ml. Fractions 25 – 52 were combined and 
evaporated to dryness and the residue crystallized from anhydrous ethanol. The crystals were 
filtered off and 0.11 g of colorless needles was obtained. This compound was identified as 
starting Nʹ-hydroxypyrazine-2-carboximidamide using melting point and NMR spectrum. 
M.p. 183.5–184.5 °C 
1H NMR spectrum (300 MHz, DMSO) δ 10.23 (1H, s, OH), 9.05 (1H, d, J = 1.4, H3), 8.64–
8.59 (2H, m, H5, H6), 5.95 (2H, bs, NH2)  









A stirred mixture of Nʹ-hydroxypyrazine-2-carboximidamide (1.38 g; 0.01 mol) and acetic 
anhydride (1.0 g; 0.01 mol) in 25 ml of xylene was heated under reflux for 3 hours. The xylene 
was evaporated under reduced pressure and the residue (1.93 g) crystallized from isopropyl 
alcohol 1.12 g (69%) of off-white small crystals was obtained. 
 
Molecular weight: 162.15 (C7H6N4O) 
Melting point: 98–99 °C (ref. [91]: 100–104 °C, isopropyl alcohol)  
 
Elemental analysis: 
 % C % H % N 
Calculated: 51.85 3.73 34.55 
Found: 51.95 4.09 34.07 
 
IR spectrum: 3079, 3024 (CH arom.), 2937 (CH aliph), 1589, 1576 (C=N), 1155 (C-O), 918 
(N-O) 
1H NMR spectrum (500 MHz, DMSO) δ 9.21 (1H, d, J = 1.5, H3), 8.86–8.82 (2H, m, H5, H6), 
2.71 (3H, s, CH3) 




4.10 3-(5-butylpyrazin-2-yl)-5-methyl-1,2,4-oxadiazole I 
 
 
A stirred mixture of 5-butyl-Nʹ-hydroxypyrazine-2-carboximidamide (1.94 g; 0.01 mol) 
and acetic anhydride (1.0 g; 0.01 mol) in 25 ml of xylene was heated under reflux for 3 hours. 
The xylene was partly evaporated under reduced pressure (approx. 1.33 kPa) and the residue 
placed to the refrigerator. A small amount of a fine precipitate separated. It was filtered off and 
dried. A light beige compound (0.20 g) was obtained. Based on NMR results it proved to be a 
mixture of starting amidoxime with a small amount of the product. 




Stationary phase – Silica gel 60 (Merck) 0,040–0,063 mm, 100 g 
Mobile phase – light petroleum + ethyl acetate 60:40 
Volume of a fraction – 25 ml 
 
Combined fractions 12–19 yielded 1.68 g of the crude product. After crystallization from 
anhydrous ethanol 0.67 g of an off-white crystals was obtained. 
 
Molecular weight: 218.26 (C11H14N4O) 
Melting point: 46.1–46.6 °C 
Elemental analysis: 
 % C % H % N 
Calculated: 60.53 6.47 25.67 
Found: 60.42 6.85 25.67 
 
IR spectrum: 2950, 2930, 2869 (CH, aliph.), 1597 (C=N), 1169 (C-O), 912 (N-O) 
1H NMR spectrum (300 MHz, DMSO) δ 9.10 (1H, s, J = 1.5, H3), 8.73 (1H, s, J = 1.5, H6), 
2.85 (2H, t, J = 7.5 Hz, CH2), 2.69 (3H, s, CH3), 1.77–1.61 (2H, m CH2), 1.41–1.24 (2H, m, 
CH2), 0.89 (3H, t, J = 7.5, CH3) 
40 
 
13C NMR spectrum (75 MHz, DMSO) δ 178.2, 166.3, 159.9, 147.7, 142.8, 139.2, 34.4, 30.7, 
21.9, 13.8, 12.2 
 
4.11 3-(5-butylpyrazin-2-yl)-5-methyl-1,2,4-oxadiazole II 
The reaction was performed as described in the previous case, but directly after the 
completed heating approx. 15 g of silica gel was added and the mixture evaporated to dryness 
and subjected to column chromatography. 
 
Chromatographic conditions: 
Stationary phase – Silica gel 60 (Merck) 0,040–0,063 mm, 100 g 
Mobile phase – light petroleum + ethyl acetate 70:30 
Volume of a fraction – 25 ml 
 
Fractions 1–7 contained only the remnants of xylene. Evaporation of fractions 8–12 yielded 
2.45 g of the crude product that was dissolved in isopropyl alcohol and left to crystallize in the 
refrigerator. Only 0.31 g of white crystals was obtained. Their purity was checked by TLC and 
by determining the melting point. The results were satisfactory and the product was submitted 
to elemental and spectral analysis. 
Molecular weight: 218.26 (C11H14N4O) 
Melting point: 47.1–47.6 °C 
Elemental analysis: 
 % C % H % N 
Calculated: 60.53 6.47 25.67 
Found: 60.32 6.76 25.44 
 
IR spectrum: 2964, 2950, 2930, 2869 (CH, aliph.), 1597 (C=N), 1168 (C-O), 912 (N-O) 
1H NMR spectrum (500 MHz, DMSO) δ 9.10 (1H, d, J = 1.5, H3), 8.73 (1H, d, J = 1.5, H6) 
2.86 (2H, t, J = 7.6 Hz, CH2), 2.70 (3H, s, CH3), 1.74–1.65 (2H, m CH2), 1.38–1.28 (2H, m, 
CH2), 0.89 (3H, t, J = 7.6, CH3) 
13C NMR spectrum (125 MHz, DMSO) δ 178.2, 166.3, 160.0, 147.7, 142.9, 139.2, 34.4, 30.7, 
21.9, 13.9, 12.2 
 






Stationary phase – Silica gel 60 (Merck) 0,040–0,063 mm, 100 g 
Mobile phase – light petroleum + ethyl acetate 80:20 
Volume of a fraction – 25 ml 
 
Evaporation of fractions 7–9 gave 2.07 g of the crude product. After crystallization from 
isopropyl alcohol 1.28 g of off-white crystals was obtained. 
Molecular weight: 218.26 (C11H14N4O) 
Melting point: 46.1–46.6 °C 
Elemental analysis: 
 % C % H % N 
Calculated: 60.53 6.47 25.67 
Found: 60.04 6.91 25.51 
 
IR spectrum: 2963, 2949, 2929, 2869 (CH-aliph.), 1596 (C=N), 1168 (C-O), 911 (N-O) 
1H NMR spectrum (500 MHz, DMSO) δ 9.10 (1H, d, J = 1.5, H3), 8.73 (1H, d, J = 1.5, H6) 
2.86 (2H, t, J = 7.6 Hz, CH2), 2.69 (3H, s, CH3), 1.73–1.65 (2H, m CH2), 1.37–1.27 (2H, m, 
CH2), 0.89 (3H, t, J = 7.6, CH3) 
13C NMR spectrum (125 MHz, DMSO) δ 178.2, 166.3, 160.0, 147.7, 142.9, 139.2, 34.5, 30.8, 




4.12 Evaluation of in vitro antifungal activity 
The antifungal activity of all compounds was evaluated by the modified microdilution 
broth CSLI standards [95, 96]. The organisms examined included Candida albicans ATCC 
44859 (American Type Culture Collection, Manassas, VA, USA, CA), Candida tropicalis 156 
(CT), Candida krusei E 28 (CK), Candida glabrata 20/I (CG), Trichosporon asahii 1188 
(TA), Aspergillus fumigatus 231 (AF), Lichtheimia corymbifera (formerly Absidia 
corymbifera) 272 (LC), and Trichophyton mentagrophytes 445 (TM). All strains tested are 
clinical isolates obtained from the Department of Clinical Microbiology, University Hospital 
and Faculty of Medicine, Charles University, Prague, Czech Republic.  
Before testing each strain was subcultured on Sabouraud dextrose agar (SDA; 
Difco/Becton Dickinson, Detroit, MI, USA) and maintained on the same medium at 4 °C. 
Fungal inocula were prepared by suspending yeasts, conidia, or sporangiospores in sterile 
0.85% saline. The cell density was adjusted using a Bürkerʼs chamber to yield a stock 
suspension of 1.0 ± 0.2 × 105 CFU/mL and 1.0 ± 0.2 × 106 CFU/mL for yeasts and molds, 
respectively. The final inoculum was made by 1:20 dilution of the stock suspension with the 
test medium. 
The compounds were dissolved in DMSO, and the antifungal activity was determined in 
RPMI 1640 media (KlinLab, Prague, Czech Republic) buffered to pH 7.0 with 0.165 M 
3-morpholinopropane-1-sulfonic acid (Sigma-Aldrich, St. Louis, MO, USA). Controls 
consisted of medium and DMSO alone. The final concentration of DMSO in the test medium 
did not exceed 1% (v/v) of the total solution. The concentrations of the studied substances 
ranged from 500 to 0.488 μmol/L. The minimum inhibitory concentration (MIC), was defined 
as 80% or greater (for yeasts and yeast-like organisms – IC80), resp. 50% or greater (for molds 
– IC50) reduction of growth in comparison with the control. The values of MICs were 
determined after 24 and 48 h of static incubation at 35 °C. In the case of T. entagrophytes, the 
MICs were recorded after 72 and 120 h due to its slow growth rate. Amphotericin B and 




Table 1. Minimum inhibitory concentrations of the tested compounds 
STRAIN 
COMPOUND – MIC/IC95 (µmol.l-1) 





24h ˃500 ˃500     ˃500 ˃500 0.020 0.82 
48h ˃500 ˃500     ˃500 ˃500 0.068 1.63 
CT 
24h ˃500 ˃500     ˃500 ˃500 0.068 1.63 
48h ˃500 ˃500     ˃500 ˃500 0.068 >417.9 
CK 
24h ˃500 ˃500     ˃500 ˃500 0.135 52.24 
48h ˃500 ˃500     ˃500 ˃500 0.135 104.47 
CG 
24h ˃500 ˃500     ˃500 ˃500 0.034 13.06 
48h ˃500 ˃500     ˃500 ˃500 0.135 52.24 
TA 
24h ˃500 ˃500     ˃500 ˃500 1.082 3.26 
48h ˃500 ˃500     ˃500 ˃500 2.164 6.53 
AF 
24h ˃500 ˃500     ˃500 ˃500 0.271 >417.9 
48h ˃500 ˃500     ˃500 ˃500 0.135 >417.9 
LC 
24h ˃500 ˃500     ˃500 ˃500 1.082 >417.9 
48h ˃500 ˃500     ˃500 ˃500 2.164 >417.9 
TM 
72h ˃500 ˃500     ˃500 ˃500 1.082 26.12 
120h ˃500 ˃500     ˃500 ˃500 1.082 52.24 
 
4.2 = Nʹ-hydroxypyrazine-2-carboximidamide 
4.3 = 5-butyl- Nʹ-hydroxypyrazine-2-carboximidamide 
4.4 = Nʹ-acetoxypyrazine-2-carboximidamide 
4.5 = Nʹ-acetoxy-5-butylpyrazine-2-carboximidamide 
4.6 = Nʹ-pivaloyloxypyrazine-2-carboximidamide 
4.7 = 5-butyl- Nʹ-pivaloyloxypyrazine-2-carboximidamide 
4.9 = 5-methyl-3-(pyrazin-2-yl)-1,2,4-oxadiazole 









4.13 Evaluation of in vitro antibacterial activity  
The antibacterial activity of all compounds was evaluated by the microdilution broth 
method [97]. The organisms examined included strains from Czech Collection of 
Microorganisms (Brno, Czech Republic): Staphylococcus aureus CCM 4516/08 (SA), 
Escherichia coli CCM 4517 (EC), Pseudomonas aeruginosa CCM 1961 (PA). These strains 
are recommended as standards for testing of antibacterial activities.  Other strains were clinical 
isolates (Department of Clinical Microbiology, University Hospital and Faculty of Medicine 
in Hradec Králové, Charles University in Prague, Czech Republic):  Staphylococcus aureus 
H 5996/08 (methicilin resistant, MRSA), Staphylococcus epidermidis H 6966/08 (SE), 
Enterococcus sp. J 14365/08 (EF),  Klebsiella pneumoniae D11750/08 (KP), Klebsiella 
pneumoniae J 14368/08 (ESBL positive, KP-E). All strains were subcultured on Mueller-
Hinton agar (MHA) (Difco/Becton Dickinson, Detroit, MI) at 35 °C and maintained on the 
same medium at 4 °C. Prior to testing, each strain was passaged onto MHA. Bacterial innocula 
were prepared by suspending in sterile 0.85% saline. The cell density of the inoculum was 
adjusted using densitometer to yield suspension of density equivalent 0,5 McFarland scale 
which is equal to a number of 1. 5 × 108 viable colony forming units (CFU)/mL.  
The compounds were dissolved in DMSO, and the antibacterial activity was determined in 
Mueller-Hinton liquid broth (Difco/Becton Dickinson, Detroit, MI), buffered to pH 7.0. 
Controls consisted of medium and DMSO alone. The final concentration of DMSO in the test 
medium did not exceed 1% (v/v) of the total solution composition. The minimum inhibitory 
concentration (MIC), defined as 95% inhibition of bacterial growth as compared to control, 
was determined after 24 and 48 h of static incubation at 35 °C. Penicillin and ciprofloxacin 
have been used as reference antibacterial drugs. 
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Table 1. Minimum inhibitory concentrations of the tested compounds 
STRAIN 
COMPOUND – MIC/IC95 (µmol.l-1) 
4.2 4.3 4.4 4.5 4.6 4.7 4.9 4.11 PEN CIPR 
SA 
24h ˃500 ˃500     ˃500 ˃500 0.24 0.98 
48h ˃500 ˃500     ˃500 ˃500 0.24 0.98 
MR 
SA 
24h ˃500 ˃500     ˃500 ˃500 125 500 
48h ˃500 ˃500     ˃500 ˃500 125 500 
SE 
24h ˃500 ˃500     ˃500 ˃500 31.25 250 
48h ˃500 ˃500     ˃500 ˃500 125 250 
EF 
24h ˃500 ˃500     ˃500 ˃500 7.81 0.98 
48h ˃500 ˃500     ˃500 ˃500 15.62 0.98 
EC 
24h ˃500 ˃500     ˃500 ˃500 125 0.06 
48h ˃500 ˃500     ˃500 ˃500 125 0.06 
KP 
24h ˃500 ˃500     ˃500 ˃500 250 0.12 
48h ˃500 ˃500     ˃500 ˃500 500 0.12 
KP-E 
24h ˃500 ˃500     ˃500 ˃500 >500 >500 
48h ˃500 ˃500     ˃500 ˃500 >500 >500 
PA 
72h ˃500 ˃500     ˃500 ˃500 >500 3.9 
120h ˃500 ˃500     ˃500 ˃500 >500 7.81 
 
4.2 = Nʹ-hydroxypyrazine-2-carboximidamide 
4.3 = 5-butyl- Nʹ-hydroxypyrazine-2-carboximidamide 
4.4 = Nʹ-acetoxypyrazine-2-carboximidamide 
4.5 = Nʹ-acetoxy-5-butylpyrazine-2-carboximidamide 
4.6 = Nʹ-pivaloyloxypyrazine-2-carboximidamide 
4.7 = 5-butyl- Nʹ-pivaloyloxypyrazine-2-carboximidamide 
4.9 = 5-methyl-3-(pyrazin-2-yl)-1,2,4-oxadiazole 





My work was concetrated on amidoximes and their O-acylated and cyclic derivatives. The 
investigation of the amidoxime derivatives is of great importance in developing a range of new 
drugs. The theoretical part deals with methods of the acylation of amidoximes in general, 
acylation using anhydrides and acyl chlorides, and finally various methods of cyclization to 
3,5-disubstituted-1,2,4-oxadiazoles were described. 
As far as the experimental part is concerned, preparation of following pyrazine 
amidoximes and derivatives was attemped: 
 5-butylpyrazine-2-carbonitrile (precursor of pyrazine amidoxime, 4.1) 
 Nʹ-hydroxypyrazine-2-carboximidamide (4.2) 
 5-butyl-Nʹ-hydroxypyrazine-2-carboximidamide (4.3) 
 Nʹ-acetoxypyrazine-2-carboximidamide (4.4) 
 Nʹ-acetoxy-5-butylpyrazine-2-carboximidamide (4.5) 
 Nʹ-pivaloyloxypyrazine-2-carboximidamide (4.6) 
 5-butyl-Nʹ-pivaloyloxypyrazine-2-carboximidamide (4.7) 
 3-[({[amino(pyrazin-2-yl)methylidene]amino}oxy)carbonyl]pyrazine-2-carboxylic 
acid (4.8) 
 5-methyl-3-(pyrazin-2-yl)-1,2,4-oxadiazole (4.9) 
 3-(5-butylpyrazin-2-yl)-5-methyl-1,2,4-oxadiazole (4.10 and 4.11) 
 
The first synthetised compound was 5-butylpyrazine-2-carbonitrile from commercially 
available pyrazinecarbonitrile. It was done in accordance with Opletalová et al. [93]. 
Nʹ-hydroxypyrazine-2-carboximidamide and 5-butyl-Nʹ-hydroxypyrazine-2-carboximid-
amide were synthesized according to Gezginci et al. [98]. 5-butyl-Nʹ-hydroxypyrazine-2-
carboximidamide is a novel compound. 
The procedure reported by Pancechowska-Ksepko et al. [71] was used for the preparation 
of the esters – Nʹ-acetoxypyrazine-2-carboximidamide and Nʹ-acetoxy-5-butylpyrazine-2-
carboximidamide. The melting point of the former ester was notably decreased in comparison 
with the data found in literature, but its purity was confirmed by the CHNS analysis. The 
difference in melting points could be due to different solvents used for the crystallization. 
Whilst the Polish authors used benzene, our product was crystallized from anhydrous ethanol.  
The latter ester is a novel compound that has not been reported in literature so far. 
I have also tried to use the same procedure for the acylation of Nʹ-hydroxypyrazine-
2-carboximidamide with the anhydride of 2,3-pyrazinedicarboxylic anhydride. Unfortunately, 
this attempt was unsuccessful, and only starting amidoxime was isolated from the reaction 
mixture. The failure can be a result of poor solubility of 2,3-pyrazinedicarboxylic anhydride in 
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toluene since precipitation of a solid was observed immediately after the addition of the 
anhydride to the solution of amidoxime. Therefore, it will be necessary to find a suitable 
solvent and perform the reaction once more. As 2,3-pyrazinecarboxylic acid is a dicarboxylic 
acid, using 2 eq. of amidoxime for 1 eq. of the anhydride could result in the desired product. 
The final experiments were focused on the preparation of 3,5-disubstituted-1,2,4-
oxadiazoles by a process patented by Fanshawe and Safir  [91]. Firstly, 5-methyl-3-(pyrazin-
2-yl)-1,2,4-oxadiazole was obtained successfully without the necessity to use column 
chromatography (part 4.9). Afterwards, during the attempt to produce 3-(5-butylpyrazin-2-yl)-
5-methyl-1,2,4-oxadiazole (part 4.10), the product contained both starting amidoxime and the 
desired product. Therefore, column chromatography was performed to separate the oxadiazole. 
Separation was succesfull, but the crystallization from ethanol yielded only 0.67 g (31%) of 
the product. 
To optimize conditions for the separation and purification of the product, the experiment 
was performed once more using a slightly modified procedure. However, the amount of the 
demanded product after crystallization from isopropyl alcohol was found low as well – only 
0.31 g (14%).  That is why mother liquid was submitted also to column chromatography. After 
the column chromatography and crystallization from isopropyl alcohol 1.28 g (59%) of 3-(5-
butylpyrazin-2-yl)-5-methyl-1,2,4-oxadiazole was obtained. Total yield of the modified 
procedure 4.11 was 1.59 g (73%). 
Due to the presence of the double bond, amidoximes can have E- or Z-configuration. In 
the NMR spectra of amidoximes prepared within this thesis, only one set of signals was found. 
Hence, only one of the possible isomers was present in the DMSO solution. It is most probably 
Z-isomer since according to the data reported in literature, unsubstituted and monosubstituted 
amidoximes exist as Z-isomers in both crystalline state and solutions [99–101]. Also, in the 
spectra of acylated amidoximes only one set of signals was observed. 
Furthermore, amidoximes and their derivatives were subjected to biological assay in order 
to evaluate their in vitro antifungal and antibacterial properties. Unfortunatelly, the results of 
the assays for amidoximes and 1,2,4-oxadiazoles were unsatisfactory. For the esters, biological 





During my diploma thesis, reaction conditions for O-acylation of amidoximes and 
formation of 1,2,4-oxadiazoles were examined. 
Acylation of amidoximes with acetic anhydride and pivalic anhydride led to corresponding 
acylated product. 
Acylation of Nʹ-hydroxypyrazine-2-carboximidamide which theoretically could yield           
3-[({[amino(pyrazin-2-yl) methylidene]amino}oxy)carbonyl] pyrazine-2-carboxylic acid, was 
not successful. 
In the end, oxadiazole preparation by heating the amidoximes in xylene gave 5-methyl-3-
(pyrazin-2-yl)-1,2,4-oxadiazole without further purification by column chromatography. On 
the other hand, in case of 3-(5-butylpyrazin-2-yl)-5-methyl-1,2,4-oxadiazole column 
chromatography was needed to separate the product from the starting 5-butylpyrazine 
amidoxime and remnants of xylene. 
Although amidoximes and oxadiazoles were not active against fungi and bacteria, further 
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